Run of bad news continues for Five Prime Therapeutics

19 February 2020

A Phase II study testing a combination of Five Prime Therapeutics’ (Nasdaq: FPRX) cabiralizumab with Opdivo (nivolumab) has missed its primary endpoint, the firm announced on Tuesday.

The trial is part of a years-long collaboration with Bristol-Myers Squibb (NYSE: BMY) to discover and develop options in immuno-oncology.

The study has been testing the combo with and without chemotherapy in people with advanced pancreatic cancer. Bristol-Myers said it has no “near term plans” for additional sponsored development of cabiralizumab.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK